Literature DB >> 17919273

Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.

E Tsochatzis1, G V Papatheodoridis, E K Manesis, G Kafiri, D G Tiniakos, A J Archimandritis.   

Abstract

BACKGROUND: The prevalence of metabolic syndrome and its possible impact on the severity of liver histological lesions have not been studied prospectively in chronic liver diseases. AIM: To investigate the prevalence of metabolic syndrome in patients with chronic viral hepatitis or non-alcoholic steatohepatitis, and to determine its associations with histological severity.
METHODS: We prospectively included 317 patients (hepatitis B e antigen-negative chronic hepatitis B: 95, chronic hepatitis C: 176, non-alcoholic steatohepatitis: 46) with liver biopsy. Metabolic syndrome was defined using the Adult Treatment Panel III criteria. Histological lesions were evaluated according to Ishak's or Brunt's classification.
RESULTS: Metabolic syndrome was present in 10.4% of patients being significantly more prevalent in non-alcoholic steatohepatitis than in chronic viral hepatitis (41.3% vs. 5.1%, P < 0.001). In chronic viral hepatitis, cirrhosis (stages 5-6) was independently associated with increasing age, higher aspartate aminotransferase and gamma-glutamyl-transpeptidase levels, severe necroinflammation and metabolic syndrome (P = 0.016). In non-alcoholic steatohepatitis, severe fibrosis (stages 3-4) was independently associated with severe necroinflammation and metabolic syndrome (P = 0.033). Presence of metabolic syndrome was not associated with presence or severity of steatosis both in chronic viral hepatitis and in non-alcoholic steatohepatitis.
CONCLUSION: Metabolic syndrome is more prevalent in non-alcoholic steatohepatitis than in chronic viral hepatitis; it is associated independently with more severe fibrosis but not with the severity of steatosis, both in chronic viral hepatitis and in non-alcoholic steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919273     DOI: 10.1111/j.1365-2036.2007.03538.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis.

Authors:  Kengo Tomita; Toshiaki Teratani; Hirokazu Yokoyama; Takahiro Suzuki; Rie Irie; Hirotoshi Ebinuma; Hidetsugu Saito; Ryota Hokari; Soichiro Miura; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2011-04-23       Impact factor: 3.199

2.  Is there any progress in the treatment of non-alcoholic fatty liver disease?

Authors:  Emmanuel A Tsochatzis; George V Papatheodoridis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-02-06

Review 3.  Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo.

Authors:  Youcai Tang
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

Review 4.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

5.  Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1.

Authors:  Qiaohua Kang; Anping Chen
Journal:  Lab Invest       Date:  2009-09-07       Impact factor: 5.662

6.  Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress.

Authors:  Jianguo Lin; Shizhong Zheng; Anping Chen
Journal:  Lab Invest       Date:  2009-10-19       Impact factor: 5.662

7.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

8.  Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis.

Authors:  Amedeo Lonardo; Stefano Ballestri; Luigi E Adinolfi; Enrico Violi; Lucia Carulli; Silvia Lombardini; Federica Scaglioni; Matteo Ricchi; Giuseppe Ruggiero; Paola Loria
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

Review 9.  The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.

Authors:  C Boutari; K Tziomalos; V G Athyros
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

10.  Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.

Authors:  Gyanranjan Rout; Saurabh Kedia; Baibaswata Nayak; Rajni Yadav; Prasenjit Das; Subrat K Acharya; Deepak Gunjan; Vishwajeet Singh; Mousumi Mahanta; Swatantra Gupta; Sandeep Aggarwal
Journal:  J Clin Exp Hepatol       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.